A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling

Gajewski, 2006, Immune suppression in the tumor microenvironment, J. Immunother., 29, 233, 10.1097/01.cji.0000199193.29048.56 Ribeiro Franco, 2020, Tumor microenvironment components: Allies of cancer progression, Pathol. Res. Pract., 216, 10.1016/j.prp.2019.152729 Principe, 2016, TGFbeta Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis, Cancer Res., 76, 2525, 10.1158/0008-5472.CAN-15-1293 Rouce, 2016, The TGF-beta/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia, Leukemia, 30, 800, 10.1038/leu.2015.327 Li, 2014, Tumor-derived transforming growth factor-beta is critical for tumor progression and evasion from immune surveillance, Asian Pac. J. Cancer Prev., 15, 5181, 10.7314/APJCP.2014.15.13.5181 Yu, 2019, TGF-beta signaling in cell fate control and cancer, Curr. Opin. Cel Biol., 61, 56, 10.1016/j.ceb.2019.07.007 Massagué, 1998, TGF-beta signal transduction, Annu. Rev. Biochem., 67, 753, 10.1146/annurev.biochem.67.1.753 Heldin, 1997, TGF-beta signalling from cell membrane to nucleus through SMAD proteins, Nature, 390, 465, 10.1038/37284 Rooke, 2001, The smad proteins and TGFbeta signalling: uncovering a pathway critical in cancer, Pathology, 33, 73, 10.1080/00313020123383 Drabsch, 2012, TGF-beta signalling and its role in cancer progression and metastasis, Cancer Metastasis Rev., 31, 553, 10.1007/s10555-012-9375-7 Bellam, 2010, Tgf-beta signaling alterations and colon cancer, Cancer Treat. Res., 155, 85, 10.1007/978-1-4419-6033-7_5 Qiu, 2007, Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4, Cancer Lett., 245, 163, 10.1016/j.canlet.2006.01.003 Kretzschmar, 2000, Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer, Breast Cancer Res., 2, 107, 10.1186/bcr42 Wang, 2000, Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers, Int. J. Oncol., 17, 1087 Xu, 2000, Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway, Proc. Natl. Acad. Sci. USA, 97, 4820, 10.1073/pnas.97.9.4820 Kim, 2000, Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis, Cytokine Growth Factor. Rev., 11, 159, 10.1016/S1359-6101(99)00039-8 Wieser, 1993, Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region, Mol. Cel. Biol., 13, 7239 Bollard, 2002, Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity, Blood, 99, 3179, 10.1182/blood.V99.9.3179 Foster, 2008, Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor, J. Immunother., 31, 500, 10.1097/CJI.0b013e318177092b Bollard, 2018, Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma, J. Clin. Oncol., 36, 1128, 10.1200/JCO.2017.74.3179 Chatterjee, 2001, GPI anchoring leads to sphingolipid-dependent retention of endocytosed proteins in the recycling endosomal compartment, EMBO J., 20, 1583, 10.1093/emboj/20.7.1583 Varshney, 2016, Lipid rafts in immune signalling: current progress and future perspective, Immunology, 149, 13, 10.1111/imm.12617 Horejsi, 2014, Membrane microdomains in immunoreceptor signaling, FEBS Lett., 588, 2392, 10.1016/j.febslet.2014.05.047 Otáhal, 2010, A new type of membrane raft-like microdomains and their possible involvement in TCR signaling, J. Immunol., 184, 3689, 10.4049/jimmunol.0902075 Davidson, 2003, Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor, Mol. Cel. Biol., 23, 2017, 10.1128/MCB.23.6.2017-2028.2003 Dinic, 2015, The T cell receptor resides in ordered plasma membrane nanodomains that aggregate upon patching of the receptor, Sci. Rep., 5, 10.1038/srep10082 Yashiro-Ohtani, 2000, Non-CD28 costimulatory molecules present in T cell rafts induce T cell costimulation by enhancing the association of TCR with rafts, J. Immunol., 164, 1251, 10.4049/jimmunol.164.3.1251 Young, 2016, T cell receptor signaling and Toll-like receptor signaling converge to amplify T cell responses, J. Immunol., 196, 128.5, 10.4049/jimmunol.196.Supp.128.5 Lewis, 2001, Calcium signaling mechanisms in T lymphocytes, Annu. Rev. Immunol., 19, 497, 10.1146/annurev.immunol.19.1.497 Trebak, 2019, Calcium signalling in T cells, Nat. Rev. Immunol., 19, 154, 10.1038/s41577-018-0110-7 Choudhry, 2001, TGF-beta abrogates TCR-mediated signaling by upregulating tyrosine phosphatases in T cells, Shock, 15, 193, 10.1097/00024382-200115030-00006 Chen, 2003, Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation, J. Exp. Med., 197, 1689, 10.1084/jem.20021170 Mayor, 2004, Sorting GPI-anchored proteins, Nat. Rev. Mol. Cel Biol., 5, 110, 10.1038/nrm1309 Sabharanjak, 2002, GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway, Dev. Cel, 2, 411, 10.1016/S1534-5807(02)00145-4 Sharma, 2002, Endocytosis of lipid rafts: an identity crisis, Semin. Cel Dev. Biol., 13, 205, 10.1016/S1084-9521(02)00049-6 Haque, 2017, Transforming growth factor-beta: A therapeutic target for cancer, Hum. Vaccin. Immunother., 13, 1741, 10.1080/21645515.2017.1327107 Gulley, 2017, Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment, J. Natl. Cancer Inst., 109, 10.1093/jnci/djw261 Fox, 1992, Transforming growth factor-beta inhibits human T-cell proliferation through multiple targets, Lymphokine Cytokine Res., 11, 299 Delisle, 2013, The TGF-beta-Smad3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells, Genes Immun., 14, 115, 10.1038/gene.2012.63 Das, 2008, TGF-beta inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the presence of sustained TCR signal transduction, J. Immunol., 180, 1490, 10.4049/jimmunol.180.3.1490 Golumba-Nagy, 2018, CD28-zeta CAR T Cells Resist TGF-beta Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop, Mol. Ther., 26, 2218, 10.1016/j.ymthe.2018.07.005 Ruffini, 1993, Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells, Cancer Immunol. Immunother., 36, 409, 10.1007/BF01742258 Mulé, 1988, Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells, Cancer Immunol. Immunother., 26, 95, 10.1007/BF00205600 Kobie, 2003, Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines, Cancer Res., 63, 1860 Kao, 2003, Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine, J. Immunol., 170, 3806, 10.4049/jimmunol.170.7.3806 Chen, 2003, TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression, Cytokine Growth Factor. Rev., 14, 85, 10.1016/S1359-6101(03)00003-0 Kloss, 2018, Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication, Mol. Ther., 26, 1855, 10.1016/j.ymthe.2018.05.003